CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · Real-Time Price · USD
0.0561
+0.0021 (3.89%)
At close: Dec 20, 2024, 4:00 PM
0.0557
-0.0004 (-0.71%)
After-hours: Dec 20, 2024, 7:59 PM EST
Company Description
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies.
The company was incorporated in 2021 and is based in South San Francisco, California.
CERo Therapeutics Holdings, Inc.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Christopher Ehrlich |
Contact Details
Address: 201 Haskins Way, Suite 230 South San Francisco, California 94080 United States | |
| Phone | 215 731 9450 |
| Website | cero.bio |
Stock Details
| Ticker Symbol | CERO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001870404 |
| ISIN Number | US71902K1051 |
| Employer ID | 87-1088814 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christopher B. Ehrlich M.B.A. | Chief Executive Officer and Chair |
| Brian G. Atwood | President and Director |
| Dr. Lawrence Corey M.D. | Co-founder and Head of Scientific Advisory Board |
| Andrew Albert Kucharchuk M.B.A. | Chief Financial Officer and Director |
| Dr. Kristen Pierce Ph.D. | Chief Development Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 17, 2024 | SCHEDULE 13G/A | Filing |
| Dec 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Dec 9, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 6, 2024 | 8-K | Current Report |
| Dec 5, 2024 | EFFECT | Notice of Effectiveness |
| Dec 5, 2024 | EFFECT | Notice of Effectiveness |
| Dec 5, 2024 | 424B3 | Prospectus |
| Dec 5, 2024 | 424B3 | Prospectus |
| Nov 27, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Nov 25, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |